Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer

  • Riva F
  • Dronov O
  • Khomenko D
 et al. 
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Pancreatic ductal adenocarcinoma (PDAC) is the most frequent pancreatic cancer type and is characterized by a dismal prognosis due to late diagnosis, local tumor invasion, frequent distant metastases and poor sensitivity to current therapy. In this context, circulating tumor cells and circulating tumor DNA constitute easily accessible blood-borne tumor biomarkers that may prove their clinical interest for screening, early diagnosis and metastatic risk assessment of PDAC. Moreover these markers represent a tool to assess PDAC mutational landscape. In this review, together with key biological findings, we summarize the clinical results obtained using "liquid biopsies" at the different stages of the disease, for early and metastatic diagnosis as well as monitoring during therapy.

Author-supplied keywords

  • Circulating tumor DNA
  • Circulating tumor cells
  • Liquid biopsy
  • Pancreatic cancer

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Francesca Riva

  • Oleksii I. Dronov

  • Dmytro I. Khomenko

  • Florence Huguet

  • Christophe Louvet

  • Pascale Mariani

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free